A. , M. A. Leggatt, G. R. Sarin, and A. , Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector. CTL, J Exp Med, vol.184, p.485, 1996.

J. C. Becker and E. Kampgen, Classical chemotherapy for metastatic melanoma, Clin Exp Dermatol, vol.25, p.503, 2000.

A. Dalgleish, The case for therapeutic vaccines, Melanoma. Res, vol.6, p.5, 1996.

R. O. Dillman, R. K. Oldham, and N. M. Barth, Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial, Cancer, vol.68, p.1, 1991.

P. S. Goedegebuure, L. M. Douville, and H. Li, Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study, J Clin Oncol, vol.13, p.1939, 1995.

L. Granziero, S. Krajewski, and P. Farness, Adoptive immunotherapy prevents prostate cancer in a transgenic animal model, Eur J Immunol, vol.29, p.1127, 1999.

P. D. Greenberg, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv Immunol, vol.49, p.281, 1991.

H. L. Hanson, D. L. Donermeyer, and H. Ikeda, Eradication of established tumors by CD8 + T cell adoptive immunotherapy, Immunity, vol.13, p.265, 2000.

F. Jotereau, M. C. Pandolfino, and D. Boudart, High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, p.405, 1991.

Y. Kawakami, S. Eliyahu, and C. Jennings, Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J Immunol, vol.154, p.3961, 1995.

J. Matthews and D. G. Altman, Statistics notes: interactions 3: how to examine heterogeneity, Br Med J, vol.313, p.862, 1996.

S. Mitsuma, H. Yoshizawa, and K. Ito, 5-S adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumourdraining lymph node cells, Immunology, vol.83, p.45, 1994.

M. C. Pandolfino, N. Labarrie`re, and M. H. Tessier, Highscale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement, Cancer Immunol Immunother, vol.50, p.134, 2001.
URL : https://hal.archives-ouvertes.fr/inserm-02482159

S. A. Rosenberg, B. S. Packard, and P. M. Aebersold, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, New Engl J Med, vol.319, p.1676, 1988.

S. A. Rosenberg, J. R. Yannelli, and J. C. Yang, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, J Natl Cancer Inst, vol.86, p.1159, 1994.

F. Ruiz-cabello, E. Klein, and F. Garrido, MHC antigens in human tumors, Immunol Lett, vol.29, p.181, 1991.

A. J. Sankoh, M. F. Huque, and S. D. Dubey, Some comments on frequently used multiple endpoint adjustment methods in clinical trials, Stat Med, vol.16, p.2529, 1997.

N. Seo, S. Hayakawa, M. Takigawa, and Y. Tokura, Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity, Immunology, vol.103, p.449, 2001.

D. Serraino and L. Fratino, Epidemiological aspects of cutaneous malignant melanoma, 1998.

, Oncol Rep, vol.5, p.905

M. H. Tessier, M. C. Pandolfino, and F. Jotereau, Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma, Eur J Cancer, vol.32, p.735, 1996.

P. A. Van-belle and R. Elenitsas, Progression-related expression of beta 3 integrin in melanomas and nevi, Hum Pathol, vol.30, p.562, 1999.

J. Withehead, The design and analysis of sequential clinical trials, 1992.